SynaptixBio Earns Second FDA Orphan Drug Designation for Rare Disease Treatment
SynaptixBio, a prominent biotech firm dedicated to combating rare and deadly diseases, has achieved a significant milestone by securing a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The company’s initial ODD, obtained in early 2023, targeted Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), the…